JB Therapeutics Inc


Overview

JBT is a clinical stage biopharmaceutical company developing a non-psychotropic synthetic derivative of THC, the active ingredient in marijuana. The first indication being pursued is scleroderma, a multibillion dollar orphan indication with high mortality and effective therapies. Due to prior investments in the clinical development of AJA for a different indication, JBT is able to reach a high ROI exit in 18 months with a $1.5M investment

Management Team

President & CEO

Mark Tepper, Ph.D.

Chief Medical Officer

Jean Claude Becker, MD

VP, Pharmaceutical Development

Ed Monaghan, Ph.D

VP Regulatory Affairs

Garol Gloff, Ph.D.

VP Toxicology

Susan Wilson, DVM, Ph.D.

Mark Tepper